In the patients with platinum-resistant ovarian cancer, combination treatment of a pan-AKT inhibitor Afursertib, Carboplatin and Paclitaxel were efficacious with an object response rate (ORR) at 32.1% [25]. Here, AKT1 is linked to ovarian carcinoma.